HUNTINGDON VALLEY, Pa.--(BUSINESS WIRE)--Immunicon Corporation (NASDAQ-GM:IMMC) announced today that it filed with the FDA a request for clearance of the CellSearch™ Circulating Tumor Cell Kit as an aid in the monitoring of patients with metastatic androgen-independent prostate cancer. Immunicon announced that it had successfully met the primary endpoint associated with its pivotal clinical trial in metastatic androgen-independent prostate cancer in January 2007. The primary endpoint required demonstrating that circulating tumor cells (CTC) levels three-to-five weeks after the initiation of chemotherapy predict overall survival.
